Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Leukemia, Myeloid, Acute 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Myelodysplastic Syndromes 4Lymphoma, Non-Hodgkin 4Leukemia, Myelomonocytic, Juvenile 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Hemoglobinuria, Paroxysmal 4Leukemia 2Hodgkin Disease 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Histiocytosis 1Hemoglobinuria 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Vorinostat 3Azacitidine 3venetoclax 2trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2olaparib 2durvalumab 2dabrafenib 2copanlisib 2aflibercept 2abiraterone 2Sunitinib 2Specimen Handling 2Sirolimus 2Nivolumab 2Immunoglobulin G 2HhAntag691 2Doxorubicin 2Disulfides 2Dasatinib 2Cyclophosphamide 2Biopsy 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Antibodies × Lymphoid × Clear all
NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Zumutor Biologics Inc.

Phase 1 Recruiting
100 enrolled
BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡